This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brito, V. N. Articles by Mendonca, B. B. Search for Related Content PubMed PubMed Citation Articles by Brito, V. N. Articles by Mendonca, B. B. Related Collections Neuroendocrinology and Pituitary Pediatric Endocrinology Female Endocrinology

Factors Determining Normal Adult Height in Girls with Gonadotropin-Dependent Precocious Puberty Treated with Depot Gonadotropin-Releasing Hormone Analogs

Disciplina de Endocrinologia da Faculdade de Medicina da Universidade de São Paulo e Unidade de Endocrinologia do Desenvolvimento e Laboratório de Hormônios e Genética Molecular LIM/42 do Hospital das Clínicas, 05403 900, São Paulo, Brasil

Address all correspondence and requests for reprints to: Vinicius N. Brito, M.D., Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, Disciplina de Endocrinologia e Metabologia. Av. Dr. Eneas de Carvalho Aguiar, 155 2°andar Bloco 6, 05403 900, São Paulo, SP, Brasil. E-mail: vinbrito{at}uol.com.br and beremen{at}usp.br.

Context: Several factors can affect adult height (AH) of patients with gonadotropin-dependent precocious puberty (GDPP) treated with depot GnRH analogs.

Objective: Our objective was to determine factors influencing AH in patients with GDPP treated with depot GnRH analogs.

Patients: A total of 54 patients (45 girls) with GDPP treated with depot GnRH analog who reached AH was included in the study.

Design: Univariate and multivariate analyses of the factors potentially associated with AH were performed in all girls with GDPP. In addition, clinical features of the girls who attained target height (TH) range were compared with those who did not. Predicted height using Bayley and Pinneau tables was compared with attained AH.

Results: In girls the mean AH was 155.3 ± 6.9 cm (–1.2 ± 1 SD) with TH range achieved by 81% of this group. Multiple regression analysis revealed that the interval between chronological age at onset of puberty and at the start of GnRH analog therapy, height SD scores (SDSs) at the start and end of therapy, and TH explained 74% of AH variance. The predicted height at interruption of GnRH therapy, obtained from Bayley and Pinneau tables for average bone age, was more accurate than for advanced bone age in both sexes. In boys the mean AH was 170.6 ± 9.2 cm (–1 ± 1.3 SDS), whereas TH was achieved by 89% of this group.

Conclusions: The major factors determining normal AH in girls with GDPP treated with depot GnRH analogs were shorter interval between the onset of puberty and start of therapy, higher height SDS at the start and end of therapy, and TH. Therefore, prompt depot GnRH analog therapy in properly selected patients with GDPP is critical to obtain normal AH.

This article has been cited by other articles:

				D Mul and I A Hughes The use of GnRH agonists in precocious puberty Eur. J. Endocrinol., December 1, 2008; 159(suppl_1): S3 - S8. [Abstract] [Full Text] [PDF]